Stock Track | Insmed Plunges 5.17% in Pre-market After Reporting Q1 2026 Losses

Stock Track

05/07

Insmed's stock experienced a significant pre-market plunge of 5.17% following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported a net loss of $163.6 million for the quarter, with a loss per share of $0.76. While this result was better than the FactSet consensus estimate of a $0.96 loss per share, investors reacted negatively to the continued substantial losses.

The company simultaneously provided a business update alongside its financial results, though specific details from that update were not immediately available in the initial reports. The market's reaction suggests concerns about Insmed's ongoing financial performance despite the earnings beat.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1151069720"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151069720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151069720?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151069720","market":"sg","top_or_hot":-1,"title":"Stock Track | Insmed Plunges 5.17% in Pre-market After Reporting Q1 2026 Losses","media":"Stock Track","content":"<p>Insmed's stock experienced a significant pre-market plunge of 5.17% following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a net loss of $163.6 million for the quarter, with a loss per share of $0.76. While this result was better than the FactSet consensus estimate of a $0.96 loss per share, investors reacted negatively to the continued substantial losses.</p><p>The company simultaneously provided a business update alongside its financial results, though specific details from that update were not immediately available in the initial reports. The market's reaction suggests concerns about Insmed's ongoing financial performance despite the earnings beat.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insmed Plunges 5.17% in Pre-market After Reporting Q1 2026 Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insmed Plunges 5.17% in Pre-market After Reporting Q1 2026 Losses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-07 19:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Insmed's stock experienced a significant pre-market plunge of 5.17% following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported a net loss of $163.6 million for the quarter, with a loss per share of $0.76. While this result was better than the FactSet consensus estimate of a $0.96 loss per share, investors reacted negatively to the continued substantial losses.</p><p>The company simultaneously provided a business update alongside its financial results, though specific details from that update were not immediately available in the initial reports. The market's reaction suggests concerns about Insmed's ongoing financial performance despite the earnings beat.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1151069720","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151069720","pubTimestamp":1778152127,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insmed's stock experienced a significant pre-market plunge of 5.17% following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported a net loss of $163.6...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"个股追踪|Insmed公布2026年第一季度亏损后盘前暴跌5.17%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"Insmed's stock experienced a significant pre-market plunge of 5.17% following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported a net loss of $163.6 million for the quarter, with a loss per share of $0.76. While this result was better than the FactSet consensus estimate of a $0.96 loss per share, investors reacted negatively to the continued substantial losses.The company simultaneously provided a business update alongside its financial results, though specific details from that update were not immediately available in the initial reports. The market's reaction suggests concerns about Insmed's ongoing financial performance despite the earnings beat.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}